earnings
confidence high
sentiment positive
materiality 0.80
Abbott Q3 sales $10.9B (+23.4%); adj. EPS $1.40 (+42.9%); raises FY guidance
ABBOTT LABORATORIES
2021-Q3 EPS reported
$2.83
revenue$31,607,000,000
- GAAP diluted EPS $1.17; adjusted diluted EPS $1.40, up 42.9% vs 3Q20.
- Global COVID-19 testing sales $1.9B; total organic sales growth 22.4%.
- Full-year 2021 GAAP EPS guidance raised to $3.55-$3.65; adjusted $5.00-$5.10.
- Board declared $0.45 quarterly dividend (payable Nov. 15, 2021); 49th consecutive annual increase.
- Acquired Walk Vascular; received FDA approvals for Amplatzer Amulet, Portico TAVR, and Talisman PFO systems.